Yan Zhou

发表

Efficacy of INtensive Treatment vs. Standard Treatment of COmpound DanshEn Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial

Yin Liu, Zhenxing Wu, Yugang Dong, 2022, Frontiers in Cardiovascular Medicine.

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

P. Sax, K. Squires, P. Cahn, 2018, Journal of acquired immune deficiency syndromes.

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

C. Katlama, Y. Yazdanpanah, K. Squires, 2017, Open forum infectious diseases.

Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors

Q. Ji, Jiankun Zhu, Yan Zhou, 2021, Diabetes Therapy.

Efficacy of INtensive Treatment vs. Standard Treatment of COmpound DanshEn Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial

Yin Liu, Zhenxing Wu, Yugang Dong, 2021, Frontiers in Cardiovascular Medicine.

The cost-effectiveness of OM-85 in managing respiratory tract infections in China

H. Yin, Shanlian Hu, J. Xuan, 2015, Journal of medical economics.

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study

Z. Yin, Z. Ye, Yan Zhou, 2022, Human vaccines & immunotherapeutics.

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

A. Rodgers, S. Moreno, Yan Zhou, 2017, The Journal of antimicrobial chemotherapy.

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

P. Sax, J. Gatell, K. Squires, 2018, Open Forum Infectious Diseases.

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2018, Open Forum Infectious Diseases.